{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:11:57Z","timestamp":1792012317104,"version":"4.4.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>We analyzed 217 patients with KMT2A-rearranged acute myeloid leukemia (AML) in 2 large sequential randomized trials. Those randomized to FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubucin) had markedly lower rates of relapse than other chemotherapy regimens. Molecular measurable residual disease assessment after cycle 2 was strongly prognostic for relapse and death. The trials were registered at the ISRCTN Registry as AML17 ISRCTN55675535 and AML19 ISRCTN78449203.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029556","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T20:57:06Z","timestamp":1754513826000},"page":"1862-1867","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Induction chemotherapy and molecular MRD influence outcomes in\n                    <i>KMT2A<\/i>\n                    -rearranged AML"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-3576","authenticated-orcid":false,"given":"Jad","family":"Othman","sequence":"first","affiliation":[{"name":"1Department of Medical and Molecular Genetics, King\u2019s College London, London, United Kingdom"},{"name":"2Department of Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"},{"name":"3Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8256-9350","authenticated-orcid":false,"given":"Nicola","family":"Potter","sequence":"additional","affiliation":[{"name":"1Department of Medical and Molecular Genetics, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-180X","authenticated-orcid":false,"given":"Sylvie D.","family":"Freeman","sequence":"additional","affiliation":[{"name":"4Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"McCarthy","sequence":"additional","affiliation":[{"name":"4Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Jovanovic","sequence":"additional","affiliation":[{"name":"1Department of Medical and Molecular Genetics, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manohursingh","family":"Runglall","sequence":"additional","affiliation":[{"name":"1Department of Medical and Molecular Genetics, King\u2019s College London, London, United Kingdom"},{"name":"5Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-0990","authenticated-orcid":false,"given":"Joanna","family":"Canham","sequence":"additional","affiliation":[{"name":"6Centre for Trials Research, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Thomas","sequence":"additional","affiliation":[{"name":"6Centre for Trials Research, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4641-835X","authenticated-orcid":false,"given":"Sean","family":"Johnson","sequence":"additional","affiliation":[{"name":"6Centre for Trials Research, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Gilkes","sequence":"additional","affiliation":[{"name":"7Department of Haematology, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Cavenagh","sequence":"additional","affiliation":[{"name":"8Haematology, St Bartholomew\u2019s Hospital, Barts Health NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Kottaridis","sequence":"additional","affiliation":[{"name":"9Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taussig","sequence":"additional","affiliation":[{"name":"10Department of Haematology, Royal Marsden Hospital, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Arnold","sequence":"additional","affiliation":[{"name":"11Clinical Haematology, Belfast City Hospital, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hemmaway","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Auckland Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Culligan","sequence":"additional","affiliation":[{"name":"13Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik Malthe","family":"Overgaard","sequence":"additional","affiliation":[{"name":"14Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-8673","authenticated-orcid":false,"given":"Mike","family":"Dennis","sequence":"additional","affiliation":[{"name":"15Haematology and Transplant Unit, The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan K.","family":"Burnett","sequence":"additional","affiliation":[{"name":"16Paul O\u2019Gorman Leukaemia Centre, Glasgow University, Glasgow, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"1Department of Medical and Molecular Genetics, King\u2019s College London, London, United Kingdom"},{"name":"2Department of Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2025111715370321400_bib1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2025111715370321400_bib2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2025111715370321400_bib3","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"42","key":"2025111715370321400_bib4","doi-asserted-by":"crossref","first-page":"26340","DOI":"10.1073\/pnas.2014732117","article-title":"Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/ KMT2A","volume":"117","author":"Bill","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"2025111715370321400_bib5","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.2008.16.7981","article-title":"Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data\u2013based meta-analysis of the German Acute Myeloid Leukemia Intergroup","volume":"27","author":"Krauter","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025111715370321400_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/leu.2012.319","article-title":"Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation","volume":"27","author":"Chen","year":"2013","journal-title":"Leukemia"},{"key":"2025111715370321400_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cancergen.2019.10.006","article-title":"Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-rearranged acute myeloid leukemia","volume":"240","author":"Vetro","year":"2020","journal-title":"Cancer Genet"},{"issue":"12","key":"2025111715370321400_bib8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2025111715370321400_bib9","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41375-024-02333-4","article-title":"Rearrangements involving 11q23.3\/KMT2A in adult AML: mutational landscape and prognostic implications \u2013 a HARMONY study","volume":"38","author":"Hern\u00e1ndez-S\u00e1nchez","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"2025111715370321400_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","article-title":"Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"2025111715370321400_bib11","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2003-02-0434","article-title":"AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases","volume":"102","author":"Schoch","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2025111715370321400_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025111715370321400_bib13","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood.2024026605","article-title":"Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia","volume":"144","author":"Loo","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025111715370321400_bib14","doi-asserted-by":"crossref","first-page":"e35717","DOI":"10.1002\/cncr.35717","article-title":"Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia","volume":"131","author":"Wang","year":"2025","journal-title":"Cancer"},{"issue":"12","key":"2025111715370321400_bib15","first-page":"1626","article-title":"The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia","volume":"90","author":"Scholl","year":"2005","journal-title":"Haematologica"},{"issue":"3","key":"2025111715370321400_bib16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1046\/j.1365-2141.2000.02076.x","article-title":"Monitoring of minimal residual disease in patients with MLL\u2013AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction","volume":"109","author":"Mitterbauer","year":"2000","journal-title":"Br J Haematol"},{"issue":"10","key":"2025111715370321400_bib17","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/sj.leu.2401542","article-title":"Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR","volume":"13","author":"Mitterbauer","year":"1999","journal-title":"Leukemia"},{"issue":"1","key":"2025111715370321400_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ped.13440","article-title":"Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia","volume":"60","author":"Matsuo","year":"2018","journal-title":"Pediatr Int"},{"issue":"2","key":"2025111715370321400_bib19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bjh.16560","article-title":"Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia","volume":"190","author":"Juul-Dam","year":"2020","journal-title":"Br J Haematol"},{"key":"2025111715370321400_bib20","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.12659\/MSM.900429","article-title":"Prognostic significance of mixed-lineage leukemia (MLL) gene detected by real-time fluorescence quantitative PCR assay in acute myeloid leukemia","volume":"22","author":"Huang","year":"2016","journal-title":"Med Sci Monit"},{"issue":"12","key":"2025111715370321400_bib21","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1038\/s41375-018-0148-3","article-title":"A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 trial","volume":"32","author":"Burnett","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2025111715370321400_bib22","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3324\/haematol.2016.141937","article-title":"Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg\/m2 with 6 mg\/m2 in the NCRI AML17 trial","volume":"101","author":"Burnett","year":"2016","journal-title":"Haematologica"},{"issue":"25","key":"2025111715370321400_bib23","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2025111715370321400_bib24","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.20.01170","article-title":"Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses","volume":"39","author":"Burnett","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025111715370321400_bib25","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1200\/JCO.23.00943","article-title":"Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations","volume":"42","author":"Russell","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"2025111715370321400_bib26","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"issue":"S1","key":"2025111715370321400_bib27","article-title":"Targeted RNA sequencing frequently identifies high-risk fusion genes in younger adults with otherwise intermediate-risk AML and isolated FLT3-ITD [abstract]","volume":"8","author":"Potter","year":"2024","journal-title":"HemaSphere"},{"issue":"15","key":"2025111715370321400_bib28","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025111715370321400_bib29","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","article-title":"Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2025","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/15\/1862\/2415833\/blood_bld-2025-029556-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/15\/1862\/2415833\/blood_bld-2025-029556-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:37:12Z","timestamp":1763411832000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/15\/1862\/546521\/Induction-chemotherapy-and-molecular-MRD-influence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":29,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,10,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029556","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,9]]},"published":{"date-parts":[[2025,10,9]]}}}